CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers by Kadouri, L et al.
Carriers of germline mutations in BRCA1 or  BRCA2 are at
substantially increased risk of both breast (BC) and ovarian cancer
(OC). There are, however, significant differences in the penetrance
estimates generated by different studies. Studies by the Breast
Cancer Linkage Consortium (BCLC) have estimated that cumula-
tive risks of BC and OC, by age 70, are approximately 70% and
40%, respectively, in BRCA1 carriers, and 70% and 27% in
BRCA2 carriers (Easton et al, 1995; Ford et al, 1998). In contrast,
risk estimates based on relatives of unselected BC and OC patients
with mutations have generally been somewhat lower (Streuwing 
et al, 1997; Thorlacius et al, 1998; Peto et al, 1999). Although
some of this difference may be due to differences in risk conferred
by different mutations, it is likely that modification of risk by other
genes or environmental risk factors clustering in families explain
most of this difference. It is also possible that these modifying
genes are associated with variation in risk in non-carriers. 
Two population-based case–control studies, based on 368 BC
cases diagnosed below age 40 (Spurdle et al, 1999) and 508 BC
cases diagnosed below age 55 (Dunning et al, 1999) respectively,
have examined the association between CAG repeat length and
BC risk, and neither found any evidence of an interaction.
However, a recent study of 304 BRCA1 carriers by Rebbeck et al
(1999) found that longer repeat lengths, particularly genotypes
with ³28 repeats, were associated with a higher risk of breast
cancer. 
In an attempt to replicate this latter observation, we have geno-
typed the AR repeats in a large series of BRCA1/2 carriers, mainly
from an Ashkenazi Jewish study in Israel. We also studied an
unselected series of Ashkenazi BC cases and controls for compar-
ison. This population has a strong founder effect such that 3 muta-
tions, the 185delAG and 5382insC mutations in BRCA1 and the
617delT mutation in BRCA2, account for almost all the BRCA1/2
carriers in this population and have a combined population
frequency of about 2.5% (Struewing et al, 1997). 
SUBJECTS AND METHODS 
Study population 
Two populations were studied; BRCA1/2 carriers and non-carrier
BC patients and controls. Blood samples from 188 BRCA1/2
carriers were identified through two centres: 142 were collected
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Summary Variation in the penetrance estimates for BRCA1 and BRCA2 mutations carriers suggests that other genetic polymorphisms 
may modify the cancer risk in carriers. A previous study has suggested that BRCA1 carriers with longer lengths of the CAG repeat in the
androgen receptor (AR) gene are at increased risk of breast cancer (BC). We genotyped 188 BRCA1/2 carriers (122 affected and 66
unaffected with breast cancer), 158 of them of Ashkenazi origin, 166 BC cases without BRCA1/2 mutations and 156 Ashkenazi control
individuals aged over 56 for the AR CAG and GGC repeats. In carriers, risk analyses were conducted using a variant of the log-rank test,
assuming two sets of risk estimates in carriers: penetrance estimates based on the Breast Cancer Linkage Consortium (BCLC) studies of
multiple case families, and lower estimates as suggested by population-based studies. We found no association of the CAG and GGC repeats
with BC risk in either BRCA1/2 carriers or in the general population. Assuming BRCA1/2 penetrance estimates appropriate to the Ashkenazi
population, the estimated RR per repeat adjusted for ethnic group (Ashkenazi and non-Ashkenazi) was 1.05 (95%CI 0.97–1.17) for BC and
1.00 (95%CI 0.83–1.20) for ovarian cancer (OC) for CAG repeats and 0.96 (95%CI 0.80–1.15) and 0.90 (95%CI 0.60–1.22) respectively for
GGC repeats. The corresponding RR estimates for the unselected case–control series were 1.00 (95%CI 0.91–1.10) for the CAG and 1.05
(95%CI 0.90–1.22) for the GGC repeats. The estimated relative risk of BC in carriers associated with ³28 CAG repeats was 1.08 (95%CI
0.45–2.61). Furthermore, no significant association was found if attention was restricted to the Ashkenazi carriers, or only to BRCA1 or
BRCA2 carriers. We conclude that, in contrast to previous observations, if there is any effect of the AR repeat length on BRCA1 penetrance,
it is likely to be weak. © 2001 Cancer Research Campaign http://www.bjcancer.com
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through the oncology department and the cancer genetic clinic in
Hadassah Medical Centre in Jerusalem, Israel and 46 through the
cancer genetic clinic in the Royal Marsden NHS Trust, London,
UK. Cases were tested on the basis of a family history of breast
and/or ovarian cancer or on the basis of their Ashkenazi origin.
The cases from Jerusalem were all but one carriers of one of the
Ashkenazi founder mutations (79: 185delAG, 20: 5382insC in
BRCA1 and 42: 6174delT in BRCA2). The UK carriers included
17 Ashkenazis (one individual carried both a 185delAG and
6174delT) and 29 other mutations (22 BRCA1; 7 BRCA2). Of the
188 carriers, 110 were affected with breast cancer, 26 with ovarian
cancer and 14 with both cancers. 36 were unaffected. The charac-
teristics of the carrier series are summarized in Table 1. 
A further 166 Ashkenazi Jewish BC patients were studied. They
were ascertained through the oncology department in Hadassah
over the period 1994–98 in the same way as the BRCA1/2 carriers
but were not found to carry any of the 3 Ashkenazi founder
BRCA1/2 mutations. 24 (14%) of the patients were diagnosed
below age 40, 54 (33%) aged 40–49 and 88 (53%) aged 50+ years.
Of them, 71/111 (64%) reported a positive family history of breast
cancer, data were not available on the rest. Thus, this series has a
slightly higher frequency of early onset cases and cases with a
family history than would be expected in the whole population. 
The controls were 152 females who took part in an independent
study into genetics of diabetes. All controls were cancer-free, from
Ashkenazi origin and aged above 56 years (mean 69, range 56–92
years). All participants signed an informed consent approved by
the institutional ethics committee. 
Genotyping methods 
Genomic DNA was extracted according to standard protocols, and
used as a template for PCR as previously described (Edwards et al,
1999). Primer sequences were 5¢-TCCGCGAAGTGATCCA-
GAAC and 5¢-CTTGGGGAGAACCATCCTCA for the CAG
repeat, and 5¢-TCCTGGCACACTCTCTTCAC and 5¢-
GCCAGGGTACCACACATCAGGT for the GGC repeat. The
forward primers were labelled by T4-PNK enzyme and 32P-dATP.
PCR reactions were conducted using Amplitaq Gold (Perkin-
Elmar) according to the manufacturer’s recommended conditions
using 0.8 and 1.3 mM MgCl2 for the CAG and GGC amplification
respectively. For the GGC reaction a 3:1 mixture of 7-deaza-
dGTP:dGTP and 2.5% v/v DMSO (Sigma, Poole, UK: molecular
grade) were used. Thermocycling conditions for the CAG amplifi-
cation were 95˚C for 9 min, 1 min at 94˚C, 30 sec at 64˚C and 1
min at 72˚C for 4 cycles, followed by a ‘touchdown’ reduction of
annealing temperature by 2˚C every 4 cycles until 54˚C, than
another 29 cycles at 54˚C annealing temperature. For the GGC
repeat a computed touchdown algorithm was used starting with
64˚C and ending at 54˚C, which is equivalent to a reduction of
0.5˚C per cycle. A further 25 cycles were conducted using an
annealing temperature of 54˚C. 
PCR products were analysed by electrophoresis in denaturing
6% polyacrylamide gels. For scoring, a ladder of samples with 15,
17, 19, 21, 23, 25, 27 CAG repeats and a sample with 16 GGC
repeats were run at regular intervals. 
Statistical analysis 
6 of the 188 carriers were excluded from all analyses: 2 for whom
the date of birth was unknown, and 4 individuals recorded as
affected but for whom the age at diagnosis was unknown. A
further 4 individuals could not be scored for the CAG repeat and
one individual for the GGC repeat, so the final analyses of the
CAG and GGC repeats were based on 178 and 181 individuals,
respectively. 
Separate analyses were performed for breast and ovarian cancer
risk. For simplicity the analyses were based on the occurrence of
the first cancer (i.e. all individuals were censored at the first
cancer). With this classification there were 118 breast cancer cases
and 29 ovarian cancer cases (including one woman diagnosed
simultaneously with both cancers and therefore counted as
affected with both cancers) and 36 unaffected carriers. 
The effects of AR genotypes on breast cancer risk in mutation
carriers were assessed using a variant of the log-rank test, based on
the statistic: 
Since the distributions of age and disease status, and also genotype
distributions, were different in the Ashkenazi and non-Ashkenazi
populations, these were treated as separate strata in the analysis. In
the above formula, Ojk is the disease status of individual k in
stratum j, Ejk is the expected cumulative incidence rate of breast
(or ovarian) cancer for the same individual, given their age and the
fact that they were a mutation carrier, and zjk is their value of the
covariate. z –
j is the mean value of the covariate in stratum j. The
significance level for U was obtained by simulation, by permuting
genotypes randomly among individuals within the same stratum.
A total of 10 000 replicates were used. This test is the locally most
powerful test for detecting an increased relative risk (constant over
age), assuming that the overall incidence rates in carriers are accu-
rately specified (D Easton, in preparation). To guard against loss of
power due to misspecification of the incidence rates, the analyses
were performed under two assumptions: (a) with the expected
incidence rates based on the BCLC studies of ‘high-risk’ BRCA1
and BRCA2 families with numerous affecteds (Easton et al, 1995;
Ford et al, 1998), and (b) with expected incidence rates half of the
BCLC incidence rates. Under assumption (b), the cumulative risk
of breast cancer by age 70 would be 0.47 in BRCA1 carriers and
0.62 in BRCA2 carriers, similar to estimates found in some of the
population studies (Streuwing et al, 1997; Thorlacius et al, 1998;
Peto et al, 1999). Since most of the carriers in this study were
ascertained on the basis of some degree of family history, it is
likely that the appropriate incidence rates fall somewhere between
these two values. 
An estimate of the relative risk is provided by exp (–U/V), with
the variance of the log-relative risk given by 1/V, where V is the
variance of U. 
For AR, the average number of repeats was first analysed as a
continuous covariate. We also performed a specific test of the
hypothesis suggested by Rebbeck et al (1999), that carriers with
³28 repeats are at increased risk of breast cancer. As a further
check we also analysed our data using Cox regression, as if the
individuals in the study represented a cohort of carriers. This anal-
ysis is not strictly justified since the individuals are selected to an
extent based on their disease status, and it cannot therefore provide
an unbiased estimate of the relative risk (though it should still
provide a valid significance test). We performed this analysis for
direct comparability with the report of Rebbeck et al (1999) who
also used this approach on a similar data set. 
U = S S (zjk - zj)(Ojk -Ejk)
jk
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The case–control analyses based on the non-carrier BC cases 
(n = 166) and controls (n = 152) were performed using a standard
logistic regression approach. All analyses were performed using 
S-Plus. 
RESULTS 
The distribution of allele sizes for the CAG and GGC repeats in
BRCA1/2 carriers, unselected BC cases and controls is presented
in Figure 1A and 1B. Mean age at BC onset was 41.6 years for all
carriers, 35.6 years in non-Ashkenazi carriers compared with 42.7
years for Ashkenzi mutation carriers. Median CAG repeat length
was significantly longer in the Ashkenazi compared with non-
Ashkenazi carriers (23 and 21 respectively, 2 sided P = 0.01); at
least one allele with repeat length ³28 was found in 17/154 (11%)
of the Ashkenazi carriers, but in none of the 30 non-Ashkenazi
carriers (Table 1). 
Median CAG repeat length was 23 repeats in carrier BC cases,
22 in ovarian cancer carriers and 21.5 in unaffected carriers. We
found no significant evidence of a trend in breast cancer with
average CAG repeat length when analysed as a continuous vari-
able (Table 2), regardless of the assumed incidence rates. Using
model (b) (incidence rates of 50% of BCLC rates) the estimated
relative risk, per repeat unit, was 1.05 (95%CI 0.94–1.17) for
breast cancer and 1.00 (95%CI 0.83–1.20) for ovarian cancer. We
also conducted analyses restricted to Ashkenazi carriers and
analysed  BRCA1 and BRCA2 carriers separately, but no significant
differences were found (data not shown). 
12 of the carriers affected with BC (11%) had at least one repeat
length of 28 or greater, compared with 2 of the ovarian cancer
cases (7%) and 2 of the unaffected carriers (6%). There was no
significant effect of the presence of one or two ³ 28 repeat allele
by any of the methods used. With assumption (b), the estimated
relative risk of breast cancer was 1.08 (95%CI 0.45–2.61), whilst
using the Cox regression approach the relative risk estimate was
reduced to 0.89 (95%CI 0.44–1.78). The only subgroup in which
there was some suggestion of an effect was in those with BRCA1
Ashkenazi mutations, where 7/71 (10%) of cases carried at least
Table 1 Clinical characteristics of carriers of BRCA1/2 mutations according to ethnic origin and AR CAG repeat length 
All carriers Non-Ashkenazia Ashkenazia
(n = 188) (n = 30) BRCA1c (n = 112) BRCA2c (n = 45) 
1. All patients
Breast cancer 122 (66%) 19 (63%) 71 (64%) 32 (71%) 
Average agee 41.6 35.6 41.6 45.1 
(range)/years (20–74) (27.6–47) (20–73) (24–52)
Unaffectedb 65 (35%) 11(37%) 41 (37%) 13 (29%) 
2. At least one CAG repeat ³28d
Breast cancer 13 (11%) 7 (10%) 5 (16%) 
Average age/yrs 47.8 47.11 47.8 
bUnaffected 4 (6%) 2 (5%) 2 (15%) 
Average age/yrs 62.75 
Total no. (%) 17 (9%) 0 10 (9%) 7 (16%) 
a’Ashkenazi origin’ includes both Israeli and British carriers of Ashkenazi founder mutations from Ashkenazi origin. bUnaffected with 
breast cancer, ovarian cancer patients included. cOne carrier of both a BRCA1 and a BRCA2 mutation not included. dFour individuals
without CAG results not included. eAge at onset was not recorded for four individuals (all BRCA1 carriers). 
Table 2 Risk for breast and ovarian cancer in BRCA1/2 carrier and in non-carrier BC cases associated with (CAG)n and (GGC)n repeats in the
AR gene 
Breast cancer RR (95% CI) Ovarian cancer RR (95% CI) 
1. CAG repeat length in AR as a continuous covariate 
BRCA1/2 carriers (a) 1.03 (0.94–1.12) 0.99 (0.82–1.19) 
(b) 1.05 (0.94–1.17) 1.00 (0.83–1.20) 
COX 1.01 (0.94–1.09) 0.98 (0.83–1.16) 
non-carrier BC cases 1.00 (0.91–1.10) 
2. ³ 28 repeats Vs < 28 repeats in AR
BRCA1/2 carriers (a) 0.89 (0.44–1.78) 0.44 (0.096–2.03) 
(b) 1.08 (0.45–2.61) 0.58 (0.13–2.59) 
COX 0.80 (0.44–1.46) 0.48 (0.11–2.05) 
non-carrier BC cases 1.27 (0.83–1.96) 
3. GGC repeat as a continuous covariate
BRCA1/2 carriers (a) 0.97 (0.84–1.13) 0.89 (0.65–1.21) 
(b) 0.96 (0.80–1.15) 0.90 (0.66–1.22) 
COX 0.99 (0.87–1.12) 0.87 (0.67–1.12) 
non-carrier BC cases 1.05 (0.90–1.22) 
RR = Relative risk. COX = Cox regression analysis. (a) Using BCLC incidence rates (b) Using 50% of BCLC incidence ratesAR polymorphisms and breast cancer risk in BRCA1/2 carriers 39
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one ³28 repeat allele, compared with 2/41 (5%). However, the
mean age of the breast cancer cases with long alleles was signifi-
cantly older than other affected carriers (47.2 vs 40.4, P = 0.04)
and the overall estimated relative risks using model (b) was still
close to 1.00 (1.15, 95%CI 0.34–3.98). 
We found no significant effect of the GGC repeat length on BC
and OC risk in carriers, for any of the methods of analysis. There
was also no significant difference in the distribution of either CAG
or GGC repeat lengths between the non-carriers, BC cases and
controls (Figure 1A, 1B and Table 2). The median CAG repeat
lengths were 22 in both the cases and controls. Repeat lengths of
28 and over were slightly more common in cases than controls
(9% Vs 6%) but again the difference and RR (1.27, 95%CI
0.83–1.96) was not statistically significant. No association of age
at BC onset with allele size was found. 
DISCUSSION 
Several genes have been suggested as potential modifiers of breast
or ovarian cancer risk, both in the general population and in
BRCA1/2 carriers. Given the hormone-dependent nature of breast
cancer, genes involved in sex steroid synthesis and metabolism,
and steroid hormone receptors, are obvious candidates. The
androgen receptor (AR) immunohistochemistry is positive in a
high proportion of BC tumours (Isola, 1993; Kuenen et al, 1996).
Androgens appear to be associated with growth inhibition in some
BC cell lines but a proliferative effect in others. In postmenopausal
women high levels of free testosterone elevate the risk for breast
cancer possibly through a direct oestrogenic effect or indirectly as
a precursor to oestrogen (Sereto et al, 1991; Cauley et al, 1999).
The AR pathways might have greater importance in premeno-
pausal women, with an oestrogen-saturated milieu (Adams, 1998).
Reports of BC risk associated with androgen levels conducted in
this age group, show contradicting results (Buldrook et al, 1977;
Sereto et al, 1989). The importance of growth-stimulating versus
growth-inhibitory AR effects remains to be elucidated. 
The AR gene, on chromosome Xq11–12, contains two trinucleo-
tide repeat polymorphisms in exon 1, the (CAG)n codes for poly-
glutamine (Sleddens et al, 1992) and (GGC)n codes for
polyglycine (Sleddens et al, 1993). They are both located in the N-
terminal domain of the receptor. The (CAG)n repeat length has
been shown to be inversely correlated with ligand-receptor tran-
scription activity (Kazemi-Esfajami et al, 1995). Rare variants
with repeat lengths >40 are responsible for X-linked spinal and
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bulbar muscular atrophy and androgen insensitivity (La Spada 
et al, 1991). A number of studies have suggested that shorter CAG
repeat length is associated with an increased risk of prostate
cancer, consistent with a higher level of androgen stimulation to
the prostate associated with a more active receptor (Hakimi et al,
1997; Ingles et al, 1997). However, not all prostate cancer case-
control studies have been able to replicate this effect (Edwards 
et al, 1999). The functional significance of the (GGC)n is unknown.
Our study, based mainly on subjects from the Ashkenazi Jewish
population, failed to find any significant association of the AR
repeat polymorphisms with risk of BC or ovarian cancer in either
BRCA1/2 carriers or in non-carriers. Rebbeck et al (1999) esti-
mated a relative risk of 1.81 (95%CI 1.06–3.08) for breast cancer
in BRCA1 carriers with at least one ³28 repeat allele. Using the
same method of analysis (Cox regression) our upper 95% confi-
dence interval excludes their estimated relative risk. As discussed
above this method does not seem appropriate (at least for relative
risk estimation) when carriers have been ascertained on the basis
of disease status and age. However, using our preferred method,
the results are qualitatively similar, although the confidence limits
on the relative risk are wider. 
Our study included data on both BRCA1 and BRCA2 carriers.
Combining data on both BRCA1 and BRCA2 mutation carriers
seems reasonable, given that both types of mutation confer similar
breast cancer risks, and that the functions of the two genes appear
to be similar. However, when restricting analysis to BRCA1
carriers (or to BRCA2 carriers) we found a similarly negative
result, although the confidence intervals were wider. We also
combined data on both Ashkenazi and non-Ashkenazi carriers.
Since the distribution of CAG repeat length differed between
populations (Edwards et al, 1992), and the distribution of disease
status and age at onset also differed (with non-Ashkenazi cases
being younger) it was necessary to correct for population in the
analysis by stratification. We did find a significantly higher age at
onset amongst Ashkenazi BRCA1 carriers with at least one ³28
repeat alleles. However, since the proportion of affected carriers
was lower in the group with a ³28 repeat allele, the estimated RR
was still close to 1.00 and non-significant. 
A recent study by Yu et al (1999) suggested an association
between shorter CAG repeat lengths and tumour grade and
survival. In our study, and in other studies of carriers, affected
carriers will be biased towards those with longer survival, and this
could introduce an artefactual association between repeat length
and disease. This effect is likely to be small, however future
studies based on incident cancers could avoid this bias. 
In conclusion, we find that AR repeat length does not have a
substantial effect on breast or ovarian cancer risk, either in BRCA1
or BRCA2 carriers, or in the general population. A larger study
would be required to detect a more moderate effect. 
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